FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294530663> ?p ?o ?g. }

• W4294530663 endingPage "1720" @default.
• W4294530663 startingPage "1705" @default.
• W4294530663 abstract "Our objective was to provide expert consensus recommendations to improve treatment tolerability through dose adjustments of concomitant antiseizure medications (ASMs) during addition of cenobamate to existing ASM therapy in adult patients with uncontrolled focal seizures.A panel of seven epileptologists experienced in the use of ASMs, including cenobamate, used a modified Delphi process to reach consensus. The panelists discussed tolerability issues with concomitant ASMs during cenobamate titration and practical strategies for dose adjustments that may prevent or mitigate adverse effects. The resulting recommendations consider concomitant ASM dose level and specify proactive (prior to report of an adverse effect) and reactive (in response to report of an adverse effect) dose adjustment suggestions based on concomitant ASM pharmacokinetic and pharmacodynamic interactions with cenobamate. Specific dose adjustment recommendations are provided.We recommend proactively lowering the dose of clobazam, phenytoin, and phenobarbital due to their known drug-drug interactions with cenobamate, and lacosamide due to a pharmacodynamic interaction with cenobamate, to prevent adverse effects during cenobamate titration. Reactive lowering of a concomitant ASM dose is sufficient for other ASMs at standard dosing owing to quick resolution of adverse effects. For carbamazepine and lamotrigine doses exceeding the upper end of standard dosing (e.g., carbamazepine, greater than 1200 mg/day; lamotrigine, greater than 500 mg/day), we encourage consideration of proactive dose reduction at cenobamate 200 mg/day to prevent potential adverse effects. All dose reductions for adverse effects can be repeated every 2 weeks as dictated by the adverse effects. At cenobamate 200 mg/day, we recommend that patients be evaluated for marked improvement of seizures and further dose reductions be considered to reduce potentially unnecessary polypharmacy.The primary goal of the recommended dose reductions of concomitant ASMs is to prevent or resolve adverse effects, thereby allowing cenobamate to reach the optimal dose to achieve the maximal potential of improving seizure control.Some people with epilepsy need to take more than one seizure medicine as part of their treatment. Taking more than one seizure medicine, however, can increase the risk of unwanted side effects. One approach to preventing side effects when adding a new seizure medicine is to lower the amount (dose) of existing seizure medicines. Cenobamate is a newer seizure medicine available in the USA for adults with focal seizures (also referred to as partial-onset seizures). Cenobamate, like many seizure medicines, must be titrated over time to a target dose. A group of epilepsy specialists met and developed recommendations for when and how to change the doses of existing seizure medicines when adding cenobamate. The goal of these recommendations is to prevent or reduce side effects like sleepiness or dizziness. The authors recommend that the dose of specific seizure medicines, including clobazam, lacosamide, phenytoin, and phenobarbital, be lowered as cenobamate is started or as cenobamate’s dose is being increased (but before side effects occur). Regular doses of other seizure medicines can be lowered if a side effect occurs because reducing the dose of the other seizure medications can often stop the side effect. These recommendations may help patients successfully reach their optimal dose of cenobamate with fewer side effects, potentially improving their seizure control. Video Abstract: Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations." @default.
• W4294530663 created "2022-09-03" @default.
• W4294530663 creator A5025122018 @default.
• W4294530663 creator A5025297509 @default.
• W4294530663 creator A5026423889 @default.
• W4294530663 creator A5028651685 @default.
• W4294530663 creator A5030901765 @default.
• W4294530663 creator A5062520786 @default.
• W4294530663 creator A5084268690 @default.
• W4294530663 date "2022-09-03" @default.
• W4294530663 modified "2023-10-10" @default.
• W4294530663 title "Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations" @default.
• W4294530663 cites W1482261919 @default.
• W4294530663 cites W1873975405 @default.
• W4294530663 cites W1960629422 @default.
• W4294530663 cites W1976354860 @default.
• W4294530663 cites W1986601214 @default.
• W4294530663 cites W2014466194 @default.
• W4294530663 cites W2017924471 @default.
• W4294530663 cites W2024087203 @default.
• W4294530663 cites W2026884709 @default.
• W4294530663 cites W2033614870 @default.
• W4294530663 cites W2069987842 @default.
• W4294530663 cites W2121613199 @default.
• W4294530663 cites W2147917303 @default.
• W4294530663 cites W2160234096 @default.
• W4294530663 cites W2166464521 @default.
• W4294530663 cites W2774662302 @default.
• W4294530663 cites W2944392111 @default.
• W4294530663 cites W2972682431 @default.
• W4294530663 cites W2988342087 @default.
• W4294530663 cites W2999475974 @default.
• W4294530663 cites W3006825878 @default.
• W4294530663 cites W3008727277 @default.
• W4294530663 cites W3017131961 @default.
• W4294530663 cites W3025465714 @default.
• W4294530663 cites W3025691036 @default.
• W4294530663 cites W3044838059 @default.
• W4294530663 cites W3080160417 @default.
• W4294530663 cites W3080518756 @default.
• W4294530663 cites W3092685772 @default.
• W4294530663 cites W3123827820 @default.
• W4294530663 cites W3147714437 @default.
• W4294530663 cites W3148524558 @default.
• W4294530663 cites W3161204932 @default.
• W4294530663 cites W3202981947 @default.
• W4294530663 cites W3207591866 @default.
• W4294530663 cites W4200594888 @default.
• W4294530663 doi "https://doi.org/10.1007/s40120-022-00400-5" @default.
• W4294530663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36057761" @default.
• W4294530663 hasPublicationYear "2022" @default.
• W4294530663 type Work @default.
• W4294530663 citedByCount "11" @default.
• W4294530663 countsByYear W42945306632023 @default.
• W4294530663 crossrefType "journal-article" @default.
• W4294530663 hasAuthorship W4294530663A5025122018 @default.
• W4294530663 hasAuthorship W4294530663A5025297509 @default.
• W4294530663 hasAuthorship W4294530663A5026423889 @default.
• W4294530663 hasAuthorship W4294530663A5028651685 @default.
• W4294530663 hasAuthorship W4294530663A5030901765 @default.
• W4294530663 hasAuthorship W4294530663A5062520786 @default.
• W4294530663 hasAuthorship W4294530663A5084268690 @default.
• W4294530663 hasBestOaLocation W42945306631 @default.
• W4294530663 hasConcept C118552586 @default.
• W4294530663 hasConcept C126322002 @default.
• W4294530663 hasConcept C177713679 @default.
• W4294530663 hasConcept C197934379 @default.
• W4294530663 hasConcept C2777288759 @default.
• W4294530663 hasConcept C2778139780 @default.
• W4294530663 hasConcept C2778186239 @default.
• W4294530663 hasConcept C2778375690 @default.
• W4294530663 hasConcept C2778802184 @default.
• W4294530663 hasConcept C2779253243 @default.
• W4294530663 hasConcept C2779384505 @default.
• W4294530663 hasConcept C42219234 @default.
• W4294530663 hasConcept C71924100 @default.
• W4294530663 hasConcept C98274493 @default.
• W4294530663 hasConceptScore W4294530663C118552586 @default.
• W4294530663 hasConceptScore W4294530663C126322002 @default.
• W4294530663 hasConceptScore W4294530663C177713679 @default.
• W4294530663 hasConceptScore W4294530663C197934379 @default.
• W4294530663 hasConceptScore W4294530663C2777288759 @default.
• W4294530663 hasConceptScore W4294530663C2778139780 @default.
• W4294530663 hasConceptScore W4294530663C2778186239 @default.
• W4294530663 hasConceptScore W4294530663C2778375690 @default.
• W4294530663 hasConceptScore W4294530663C2778802184 @default.
• W4294530663 hasConceptScore W4294530663C2779253243 @default.
• W4294530663 hasConceptScore W4294530663C2779384505 @default.
• W4294530663 hasConceptScore W4294530663C42219234 @default.
• W4294530663 hasConceptScore W4294530663C71924100 @default.
• W4294530663 hasConceptScore W4294530663C98274493 @default.
• W4294530663 hasFunder F4320318186 @default.
• W4294530663 hasIssue "4" @default.
• W4294530663 hasLocation W42945306631 @default.
• W4294530663 hasLocation W42945306632 @default.
• W4294530663 hasLocation W42945306633 @default.
• W4294530663 hasOpenAccess W4294530663 @default.
• W4294530663 hasPrimaryLocation W42945306631 @default.

• next